Literature DB >> 10651202

Pulmonary ventricular outflow reconstruction with a size-reduced cryopreserved pulmonary valve allograft: mid-term follow-up.

Y Yoshikawa1, S Kitamura, S Taniguchi, Y Kameda, K Niwaya, H Sakaguchi.   

Abstract

Surgical reduction of pulmonary allografts is being performed because of the shortage of allografts of suitable size for pediatric use. However, the outcome of size-reduced pulmonary allografts for pulmonary conduits is unknown. In the present study, cryopreserved pulmonary allografts harvested from adults at the time of kidney donation were size-reduced and used in 4 children, 2 with pulmonary atresia and ventricular septal defect and 2 with atrioventricular discordance, pulmonary atresia and ventricular septal defect. They all had undergone right and/or left modified Blalock-Taussig shunt operations with a 5-mm synthetic graft prior to the reparative operations. They underwent definitive repair with a size-reduced cryopreserved pulmonary allograft valved conduit and were followed up for 2-5 years. Postoperative echocardiographic and cineangiographic assessments revealed excellent function of the pulmonary bicuspidalized valves with a minimal pressure gradient and no, or only trivial, regurgitation. Although the long-term result of a cryopreserved bicuspid pulmonary valved conduit remains unknown, the remodeled bicuspid pulmonary allograft conduits showed excellent hemodynamic characteristics in mid-term follow-up and appear to be a reasonable alternative to other types of conduits when an appropriate-sized allograft is not available.

Entities:  

Mesh:

Year:  2000        PMID: 10651202     DOI: 10.1253/jcj.64.23

Source DB:  PubMed          Journal:  Jpn Circ J        ISSN: 0047-1828


  1 in total

1.  Mid- to long-term outcomes of cardiovascular tissue replacements utilizing homografts harvested and stored at Japanese institutional tissue banks.

Authors:  Soichiro Kitamura; Toshikatsu Yagihara; Junjiro Kobayashi; Hiroyuki Nakajima; Koichi Toda; Tomoyuki Fujita; Hajime Ichikawa; Hitoshi Ogino; Takeshi Nakatani; Shigeki Taniguchi
Journal:  Surg Today       Date:  2011-03-23       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.